AstraZeneca Bets $2 Billion on Summit’s Cancer Breakthrough

The collaboration centers on ivonescimab, a bispecific antibody designed to strike tumors through two simultaneous pathways. By blocking both the PD-1 immune brake and the VEGF protein responsible for vascular growth, the drug effectively starves tumors while mobilizing the immune system. Soriot positions this dual-action approach as a successor to the current generation of PD-1 inhibitors, such as Merck’s blockbuster Keytruda.

Ivonescimab gained significant industry attention after head-to-head trials demonstrated superior efficacy against Keytruda in patients with advanced non-small cell lung cancer. AstraZeneca now intends to integrate this asset with its own proprietary portfolio of antibody-drug conjugates, aiming to create more potent, multi-layered treatment regimens.